Repurposing TAK-285 as An Antibacterial Agent against Multidrug-Resistant Staphylococcus aureus by Targeting Cell Membrane
Current Microbiology · 2025
DOI: 10.1007/s00284-024-04001-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Microbiology, 2025. Verfasst von Jinlian Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, Guangdong, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Biofilms, Microbial Sensitivity Tests, Methicillin-Resistant Staphylococcus aureus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Infections and antimicrobial resistance are becoming serious global public health crises. Multidrug-resistant Staphylococcus aureus (S. aureus) infections necessitate novel antimicrobial development. In this study, we demonstrated TAK-285, a novel dual HER2/EGFR inhibitor, exerted antibacterial activity against 17 clinical methicillin-resistant S. aureus (MRSA) and 15 methicillin sensitive S. aureus (MSSA) isolates in vitro, with a minimum inhibitory concentration (MIC) of 13.7 μg/mL. At 1 × MIC, TAK-285 completely inhibited the growth of S. aureus bacterial planktonic cells, and at 2 × MIC, it exhibited a superior inhibitory effect on intracellular S. aureus SA113-GFP compared to linezolid. Moreover, TAK-285 effectively inhibited biofilm formation at sub-MIC, eradicated mature biofilm and eliminated bacteria within biofilms, as confirmed by CLSM. Furthermore, the disruption of cell membrane permeability and potential was found by TAK-285 on S. aureus, suggesting its targeting of cell membrane integrity. Global proteomic analysis demonstrated that TAK-285 disturbed the metabolic processes of S. aureus, interfered with biofilm-related gene expression, and disrupted membrane-associated proteins. Conclusively, we repurposed TAK-285 as an antimicrobial with anti-biofilm properties against S. aureus by targeting cell membrane. This study provided strong evidence for the potential of TAK-285 as a promising antimicrobial agent against S. aureus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, Guangdong, China.
- Department of Infectious Diseases and Shenzhen Key Laboratory for Endogenous Infections, Huazhong University of Science and Technology Union Shenzhen Hospital, No. 89 Taoyuan Road, Nanshan District, Shenzhen, 518052, Ch…
- School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, Guangdong, China. qiwendeng@hotmail.com.
Förderung
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Huang, J., Xu, Z., He, P., Lin, Z., Peng, R., Yu, Z., Li, P., Deng, Q., & Liu, X. (2025). Repurposing TAK-285 as An Antibacterial Agent against Multidrug-Resistant Staphylococcus aureus by Targeting Cell Membrane. Current Microbiology. https://doi.org/10.1007/s00284-024-04001-3
Vancouver
Huang J, Xu Z, He P, Lin Z, Peng R, Yu Z, et al. Repurposing TAK-285 as An Antibacterial Agent against Multidrug-Resistant Staphylococcus aureus by Targeting Cell Membrane. Current Microbiology. 2025. doi:10.1007/s00284-024-04001-3
BibTeX
@article{Huang2025,
author = {Huang, Jinlian and Xu, Zhichao and He, Peikun and Lin, Zhiwei and Peng, Renhai and Yu, Zhijian and Li, Peiyu and Deng, Qiwen and Liu, Xiaoju},
title = {Repurposing TAK-285 as An Antibacterial Agent against Multidrug-Resistant Staphylococcus aureus by Targeting Cell Membrane},
journal = {Current Microbiology},
year = {2025},
doi = {10.1007/s00284-024-04001-3}
}
EUVIMED